Vinit Shah1*, Panneer Selvam V2, Sindhanai VP1, Shobita Nair2, Amal Gupta2 and Radha Jayaraman2
1Retina and Vitreous Services, Arasan Eye Hospital, Erode, Tamil Nadu, India
2Cataract Services, Arasan Eye Hospital, Erode, Tamil Nadu, India
*Corresponding Author: Vinit Shah, Retina and Vitreous Retina and Vitreous Services, Arasan Eye Hospital, Erode, Tamil Nadu, India.
Received: September 07, 2020; Published: September 23, 2020
Aim: Evaluation of the efficacy of single-dose intravitreal Bevacizumab in the management of macular edema due to retinal vein occlusions.
Methods: This study was an Institutional Review Board approved prospective interventional study done in a Retina clinic at a tertiary eye hospital, where 45 patients were enrolled. All patients clinically diagnosed to have retinal vein occlusions with macular edema with all risk factors were enrolled for the study. After informed consent, all participants were subjected to the following examinations, visual acuity was recorded on Snellen’s vision chart, followed by anterior segment evaluation, intraocular pressure, gonioscopy, slit-lamp biomicroscopy with 90D lens and fundus finding were confirmed by indirect ophthalmoscopy. Optical coherence tomography was done in every patient. The diagnosis of macular edema was established by clinical examination and optical coherence tomography was done to quantify central macular thickness (CMT) at baseline, 4 weeks and 8 weeks after a single injection of 1.25 mg (0.05 ml) intravitreal Bevacizumab.
Results: The mean central macular thickness (CMT) at presentation was 482.88 µm ± 173.6 µm (SD). The mean CMT decreased from baseline to 314.3 µm ± 129.9 µm at one month. The mean CMT decreased to 237.1 µm ± 97.08 µm at the end of 2 months which was statistically significant (p < 0.05). The logarithm of minimal angle of resolution (logMAR) vision at presentation 1.043 ± 0.443 improved to 0.690 ± 0.424 and 0.529 ± 0.440 at 1 month and 2 months respectively (p < 0.05). There was no statistically insignificant change in IOP after a single injection of Bevacizumab.
Conclusion: Intravitreal Bevacizumab even in a single dose is effective in the treatment of all types of retinal vein occlusions. There was a statistically significant improvement in visual acuity, the decrease in the central macular thickness was also statistically significant and effects were maintained throughout the follow-up period without any changes in IOP.
Keywords: Retinal Vein Occlusions; Macular Edema; Intravitreal Bevacizumab; Optical Coherence Tomography; Center Macular Thickness; Visual Acuity; Intraocular Pressure
Citation: Vinit Shah., et al. “Evaluation of the Efficacy of Single Dose of Intravitreal Bevacizumab in the Management of Macular Edema due to Retinal Vein Occlusions". Acta Scientific Paediatrics 3.10 (2020): 12-19.
Copyright: © 2020 Vinit Shah., et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.